Table 3.

Clinical Trials Involving SGT for HGG Treatment

Trial No.	Start– Completiona	Phase	Patients	Vector Used	Suicide Gene/ Prodrug	Combination	Result	Citation
NCT00751270	2005–2011	Ib	Newly diagnosed HGG	AdV	HSV1-TK/ valACV	RT+TMZb	Safety assessed	20
NCT00589875	2007–2015	Iia	Newly diagnosed HGG	AdV	HSV1-TK/ valACV	RT+TMZb	Safety assessed	45
NCT00870181	2008–2012	II	Recurrent HGG	AdV	HSV1-TK/ GCV	N/A	Improved survival	42
NCT01172964	2010–2015	I	Recurrent HGG	NSC(HB1. F3.CD)	bCD/5FC		Safety assessed	46
NCT00634231	2010–2015	I	Newly diagnosed HGG (pediatric)	AdV	HSV1-TK/ valACV	RT+TMZb	Safety assessed/ ongoing	47
NCT01156584	2010–2016	I	Recurrent HGG	RRV	yCD/5FC	N/A	—	—
NCT01470794	2012–2016	I	Recurrent HGG (undergoing surgery)	RRV	yCD/5FC	N/A	Safety + encouraging efficacy	48,49
NCT01985256	2014–2016	I	Recurrent HGG (undergoing surgery)	RRVc	yCD/5FC	N/A	—	—
NCT02015819	2014–2019	I	Recurrent HGG	NSC(HB1. F3.CD)	bCD/5FC+ Leucovorin	N/A	Ongoing
NCT01811992	2014–2020	I	Newly diagnosed HGG	AdV	HSV1-TK/ valACV	AdV-Flt3L	Ongoing	—
NCT02414165	2015–2019	II-III	Recurrent HGG	RRV	yCD/5FC	—	—	50
NCT02192359	2016–2020	I	Recurrent HGG	HB1. F3.CD21. hCE1m6	hCE1m6/ irinotecan	—	Ongoing	—
NCT03596086	2017–2023	I-II	Recurrent HGG	AdV	HSV1-TK/ valACV	RT+TMZ	Ongoing	—
NCT03603405	2018–2023	I-II	Newly diagnosed HGG	AdV	HSV1-TK/ valACV	RT+TMZ	Ongoing	—
NCT03576612	2018–2021	PI	Newly diagnosed HGG	AdV	HSV1-TK/ valACV	RT+ Nivolumab+TMZb	Ongoing	—
NCT02598011	2016–2022	I	Newly diagnosed HGG	RRV	yCD/5FC	RT+TMZ	Planned	—

Only the trials carried on/undertaken/planned since 2010 are mentioned here. See review from Kaufmann et al.³⁶ where some of the trials before 2010 are discussed.

^aPrimary completion.

^bTMZ allowed after prodrug administration.

^cIntravenous administration.